Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.

Blumsohn A, Marin F, Nickelsen T, Brixen K, Sigurdsson G, González de la Vera J, Boonen S, Liu-Léage S, Barker C, Eastell R; EUROFORS Study Group..

Osteoporos Int. 2011 Jun;22(6):1935-46. doi: 10.1007/s00198-010-1379-y. Epub 2010 Oct 12.

2.

Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS.

Lyritis G, Marin F, Barker C, Pfeifer M, Farrerons J, Brixen K, del Pino J, Keen R, Nickelsen TN; EUROFORS Study Group..

Curr Med Res Opin. 2010 Aug;26(8):1799-807. doi: 10.1185/03007995.2010.488516.

PMID:
20482322
3.

Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study.

Minne H, Audran M, Simões ME, Obermayer-Pietsch B, Sigurðsson G, Marín F, Dalsky GP, Nickelsen T; EUROFORS Study Group..

Curr Med Res Opin. 2008 Nov;24(11):3117-28. doi: 10.1185/03007990802466595. Epub 2008 Oct 6.

PMID:
18838053
4.

Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.

Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T; EUROFORS Investigators..

J Bone Miner Res. 2008 Oct;23(10):1591-600. doi: 10.1359/jbmr.080506.

5.

Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.

Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV; EUROFORS Investigators..

J Clin Endocrinol Metab. 2008 Mar;93(3):852-60. Epub 2007 Dec 26.

PMID:
18160462

Supplemental Content

Loading ...
Support Center